T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Microchip Technology
MCHP
$43.1B
| $900M | 0.14% |
26,547,014
-6,212,678
| -19% | -$292M |
|
152
Amgen
AMGN
$225B
| $899M | 0.14% |
4,435,045
+507,220
| +13% | +$111M |
|
153
Walmart Inc
WMT
$923B
| $891M | 0.14% |
23,532,759
-511,005
| -2% | -$19.7M |
|
154
Textron
TXT
$15.3B
| $888M | 0.14% |
33,312,624
+1,477,882
| +5% | +$59.7M |
|
155
Conagra Brands
CAG
$7.16B
| $880M | 0.14% |
29,996,118
-6,884,302
| -19% | -$207M |
|
156
Las Vegas Sands
LVS
$29.6B
| $879M | 0.14% |
20,699,689
-1,073,267
| -5% | -$65M |
|
157
Lam Research
LRCX
$408B
| $866M | 0.14% |
36,087,130
+16,295,000
| +82% | +$469M |
|
158
MetLife
MET
$61.4B
| $858M | 0.14% |
28,063,913
+5,864,757
| +26% | +$260M |
|
159
Home Depot
HD
$342B
| $856M | 0.14% |
4,582,863
+251,522
| +6% | +$55.2M |
|
160
Goldman Sachs
GS
$302B
| $855M | 0.14% |
5,528,708
+4,240,486
| +329% | +$900M |
|
161
AT&T
T
$166B
| $846M | 0.13% |
38,415,753
-2,216,227
| -5% | -$60.5M |
|
162
Gilead Sciences
GILD
$168B
| $828M | 0.13% |
11,080,459
+120,795
| +1% | +$8.35M |
|
163
Citigroup
C
$231B
| $828M | 0.13% |
19,654,201
+4,677,162
| +31% | +$314M |
|
164
Northrop Grumman
NOC
$82B
| $821M | 0.13% |
2,713,080
-509,536
| -16% | -$177M |
|
165
Datadog
DDOG
$86.5B
| $818M | 0.13% |
22,744,350
+18,188,764
| +399% | +$750M |
|
166
Entegris
ENTG
$24.6B
| $815M | 0.13% |
18,214,056
+94,123
| +0.5% | +$4.88M |
|
167
Ascendis Pharma A/S
ASND
$16.8B
| $810M | 0.13% |
7,192,829
-568,467
| -7% | -$73.9M |
|
168
West Pharmaceutical
WST
$24.8B
| $810M | 0.13% |
5,319,284
-1,511,705
| -22% | -$233M |
|
169
Air Products & Chemicals
APD
$67.7B
| $808M | 0.13% |
4,048,774
-928,831
| -19% | -$212M |
|
170
Paycom
PAYC
$9.52B
| $807M | 0.13% |
3,997,002
+131,334
| +3% | +$36M |
|
|
PFPT
171
DELISTED
Proofpoint, Inc.
PFPT
| $797M | 0.13% |
7,773,073
-535,425
| -6% | -$62.4M |
|
172
Trip.com Group
TCOM
$28.7B
| $796M | 0.13% |
33,926,092
+1,949,269
| +6% | +$60.8M |
|
173
Shopify
SHOP
$194B
| $790M | 0.12% |
18,968,350
-7,210,310
| -28% | -$325M |
|
|
BDXA
174
DELISTED
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6
BDXA
| $777M | 0.12% |
14,181,480
-107,288
| -0.8% | -$6.49M |
|
175
Avantor
AVTR
$9.42B
| $774M | 0.12% |
61,969,628
+3,113,680
| +5% | +$49.9M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.